Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16200110 | 0.65 | PDE3B (0.37) | PDE3BPDE3ACYP2E1CYP2A6CYP1A2 | |
| SCHEMBL1368375 | 0.63 | NR2E1 (0.47) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10444945 | 0.63 | PDE3B (0.39) | PDE3BPDE3ACYP2E1CYP2A6CYP1A2 | |
| SCHEMBL13683029 | 0.63 | PDE3B (0.36) | PDE3BPDE3ACYP2E1CYP2A6CYP1A2 | |
| SCHEMBL16914399 | 0.61 | NR2E1 (0.42) | PDE3BPDE3ACYP2E1CYP2A6CYP1A2 | |
| SCHEMBL25187570 | 0.61 | HTT (0.49) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19272800 | 0.61 | CYP1A2 (0.56) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22199031 | 0.60 | KDM4E (0.48) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12918513 | 0.60 | CYP2E1 (0.42) | PDE3BPDE3ACYP2E1CYP2A6CYP1A2 | |
| SCHEMBL14932367 | 0.59 | PSEN1 (0.44) | PDE3BPDE3ACYP2E1CYP2A6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | disclosed |
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | AVPR2, CRHR1, CRHR2 | PDE3B 408/4885PDE3A 332/4885CYP2E1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.